[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567210":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":29,"studyPopulation":22,"armGroups":30,"interventions":37,"overallOfficials":45,"centralContacts":49,"locations":22,"responsibleParty":55,"collaborators":22,"id":58,"slug":22,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":22,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":22,"enrollmentInfo":66,"targetDuration":22,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":22,"overallStatus":75,"whyStopped":22,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":22},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"Overall Response Rate (ORR)","ORR was defined as the proportion of patients who achieved CR or PR as their best response","1 year",[14,18],{"measure":15,"description":16,"timeFrame":17},"Overall Survival (OS)","OS was defined as time from diagnosis to death from any cause or the last follow-up","through study completion, an average of 2 years",{"measure":19,"description":20,"timeFrame":21},"Progression Free Survival (PFS)","Progression was defined according to the Lugano Response Criteria","2 years",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":22,"primaryPurpose":26,"observationalModel":22,"timePerspective":22,"maskingInfo":27},"NA","SINGLE_GROUP","TREATMENT",{"masking":28,"maskingDescription":22,"whoMasked":22},"NONE","The investigators will evaluate safety and efficacy of G-Pola-ZLP as induction therapy in Previously Untreated Diffuse Large B-Cell Lymphoma. ORR(Overall response rate, progression-free survival (PFS), Overall survival (OS), Adverse events (AEs) will be assessed.",[31],{"label":32,"type":33,"description":34,"interventionNames":35},"Induction Therapy","EXPERIMENTAL","Patients were treated by G-Pola-ZLP as Induction Therapy",[36],"Drug: Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy",[38],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"DRUG","Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy","Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg\u002Fkg iv qd d1), Zanubrutinib(160mg po bid d1-21), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg\u002Fm2 po qd d1-5) as induction therapy.",[32],[44],"G-Pola-ZLP",[46],{"name":47,"affiliation":5,"role":48},"Liren Qian, PhD","PRINCIPAL_INVESTIGATOR",[50,54],{"name":47,"role":51,"phone":52,"phoneExt":22,"email":53},"CONTACT","+861066947194","qlr2007@126.com",{"name":47,"role":51,"phone":22,"phoneExt":22,"email":22},{"type":48,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Liren Qian","Associate Chief Physician, Associate Professor","100567210",false,"NCT06665217","G-Pola-ZLP in Diffuse Large B-Cell Lymphoma","Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Patient has not received chemotherapy previously.\n* Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women","ALL","14 Years",{"count":67,"type":68},80,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.",[74],"Diffuse Large B-Cell Lymphoma","NOT_YET_RECRUITING","2025-08-13",{"date":78,"type":79},"2025-08-14","ACTUAL",{"date":81,"type":68},"2025-09-24",{"date":83,"type":68},"2030-01",{"name":5,"class":6}]